Member Info for bp82

So can you use listed companies money to apply for a patent in your own name without approval from share holders??

There is no email.

Its all B****. I tried to look around on internet and found no reference of patents been granted to GM. All says Valirx.

b h a n u 1 2 5 8 2 at y a h o o . c o m

Hi guys, could I also have a copy of the email.

Have a huge sum invested here :(
bhanu12582**********

https://www.bbc.com/future/article/20200124-why-brca-cancer-genes-need-to-be-rebranded-for-men

https://www.bbc.com/news/health-51263384

all sounds so promising then what is holding this up

http://investor.sierraoncology.com/2019-06-01-Sierra-Announces-Promising-Preliminary-Efficacy-in-SRA737-Clinical-Program-Outlines-Potential-Path-to-Registration

Be optimistic rightback ;)

https://walletinvestor.com/lse-stock-forecast/val-stock-prediction

Thats all I need :)

Hi Rightback, post has just arrived.

They are opening it and will let you know ASAP ;;;)))

How long does it usually takes to collect all data and submit application?

Scientific Summary:

· All data collected to date during the clinical trial of VAL201, is currently being reviewed and collated by the data analytics team.

· The data will be secured after it has been entered into the record, collated and verified, whilst some additional data is still to be collected from various providers, contractors and from patients and then entered into the record.

· Beyond the fundamental safety and tolerability endpoints for the trial, the study is providing accurate pharmacokinetic information about the uptake, distribution, metabolism and elimination of the compound in humans. As such, VAL201 continues to address its endpoints in its first-in-human study.

· A late-stage study designed to determine the overall effectiveness of VAL201 and the most effective therapeutic strategies for its use in disease management, is now possible. This late-stage study will be designed and set up, in parallel to the conclusion of the current early-stage Phase I/IIa trial.



VAL201 has been developed in collaboration with Cancer Research (CRUK) and is a decapeptide with potential in treating hormone-dependent and hormone-independent prostate cancer, currently a poorly served multi-billion dollar commercial market.

SAN FRANCISCO (Reuters) - Eli Lilly and Co (N:LLY) aims to announce roughly one $1 billion (765 million pounds) to $5 billion (3.8 billion pounds) deal every quarter in 2020, its chief financial officer told Reuters, as the U.S. drugmaker looks to build up its pipeline of future products.
It will focus largely on earlier stage opportunities across key therapeutic areas including oncology, pain, immunology, and neurology, CFO John Smiley told Reuters in an interview at the JP Morgan Healthcare conference in San Francisco earlier this week.

Eli Lilly has been on a deal-making spree in recent years in a bid to increase products and sales in core franchises as older blockbuster medicines, such as diabetes treatment Humalog, face generic competition and pressure to lower prices.

The whole point here is that why no pharma is interested in 401. Why such means to raise funds. Is it any good for treatment.

10 p OK
30 p makes me happy
50 p Burj Dubai
£1 retirement :)

When its gets there soon, I will buy more of PYC and VAL ;;;)))

I will be over the moon if I could get my money back. Anything on top will be a BONUS ;)

from me.

F*** George hard.

I dont think these are sells.

No one in their right mind would sell at such prices.